Zealand Pharma



Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company's lead product is lixisenatide (Lyxumia®), a once-daily GLP-1 agonist, discovered by Zealand Pharma and licensed to Sanofi for the treatment of Type-2 diabetes.  In October 2011, Sanofi submitted an MAA for lixisenatide in Europe and submission for regulatory approval in the United States is planned for Q4 2012. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a licence agreement with Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy- induced diarrhea.

Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs, and all drug candidates in its pipeline have been identified through the company's own drug discovery activities. Zealand Pharma's products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. 

Annual Report 2010      Fact Sheet
                                                  

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.



Zealand Drugs